ICON Appoints President of Early-Phase Division

Dr. Mario Rocci has been appointed president of ICON Development Solutions, the company’s Early-Phase Division. Dr. Rocci joined the company through the acquisition of Prevalere Life Sciences in 2008, where he served as chief executive officer. Since that time he has led ICON’s global bioanalytical business. He has more than 29 years of experience in the pharmaceutical industry and prior to joining Prevalere in 1988, held the position of head of the Laboratory of Investigative Medicine and Research Associate Professor of Medicine at Thomas Jefferson University.

Dr. Rocci succeeds Dr. Thomas Frey, who will retire in 2012. Dr. Frey will now lead one of the company’s change management projects.

Peter Gray, chief executive officer of ICON, said, “Mario has done an excellent job in building and shaping our bioanalytical capabilities and under his tenure we have been successful in forming strategic partnerships in this area with some large pharma clients. Building on Thomas’ work, Mario’s deep scientific knowledge and industry experience will be invaluable as we look to strengthen our early phase business and help clients through the dynamic changes impacting the drug development process.”